Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up

Paz, Isabel Pavón de; Sierra, José Antonio Rosado; Blanco, Carmen Pérez; Móstoles, N. Modroño; Armas, Guadalupe Guijarro de; Aguilera, Cristina

doi:10.1016/j.endien.2019.02.001

Cited by 3 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Maines et al demonstrated that Vitamin D, in addition to its therapeutic role (i.e., increased calcium absorption, better mineralization), also plays a preventive role in bisphosphonate-induced hypocalcemia [ 27 ]. In fact, higher basal vitamin D levels have been shown to reduce the risk of post-infusion hypocalcemia after neridronate treatment in children and adolescents [ 27 ] and zoledronic acid in adults [ 29 ]. It was found that hypocalcemia was mild and asymptomatic in all cases and calcium levels at baseline and post-infusion (after 24 and 48 h) were related to baseline vitamin D levels, with a positive linear correlation [ 29 ].…”

Section: Resultsmentioning

confidence: 99%

“…In fact, higher basal vitamin D levels have been shown to reduce the risk of post-infusion hypocalcemia after neridronate treatment in children and adolescents [ 27 ] and zoledronic acid in adults [ 29 ]. It was found that hypocalcemia was mild and asymptomatic in all cases and calcium levels at baseline and post-infusion (after 24 and 48 h) were related to baseline vitamin D levels, with a positive linear correlation [ 29 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D and Osteogenesis Imperfecta in Pediatrics

et al. 2023

View full text Add to dashboard Cite

Osteogenesis Imperfecta (OI) is a heterogeneous group of inherited skeletal dysplasias characterized by bone fragility. The study of bone metabolism, in these disease, is problematic in terms of clinical and genetic variability. The aims of our study were to evaluate the importance of Vitamin D levels in OI bone metabolism, reviewing studies performed on this topic and providing advice reflecting our experience using vitamin D supplementation. A comprehensive review on all English-language articles was conducted in order to analyze the influence of vitamin D in OI bone metabolism in pediatric patients. Reviewing the studies, contradictory data were found on the relationship between 25OH vitamin D levels and bone parameters in OI, and in several studies the baseline levels of 25OH D were below the threshold value of 75 nmol/L. In conclusion, according to the literature and to our experience, we highlight the importance of adequate vitamin D supplementation in children with OI.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Vitamin D and Osteogenesis Imperfecta in Pediatrics

et al. 2023

View full text Add to dashboard Cite

show abstract

“…On day 14, ZA release from the scaffolds caused a large difference in the amount of calcium deposited. The Bone Mineral Density (BMD) and osteogenic ability of ZA have been widely investigated and different mechanisms have been discussed ( Pavón de Paz et al, 2019 ; Jin et al, 2020 ). In previous studies on ZA, the rate of increase in calcium deposits was observed with increasing time, the amount of calcium islets on the 14th day was significantly higher than the 7th day, which is consistent with our present study that the deposits Calcium has increased over time and the amount of ZA in the scaffold has increased ( Raina et al, 2020 ; Demir-Oğuz and Ege, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

Osteogenesis Improvement of Gelatin-Based Nanocomposite Scaffold by Loading Zoledronic Acid

Abdulahy

Bidhendi

Vaezi

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Bisphosphonates (BPs) such as Zoledronic acid (ZA) are a subset of synthetic small molecules, which are now marketed as the main drugs to stimulate the growth and differentiation of osteoblast cells, thereby increasing bone formation as well as preventing bone loss. Also, Halloysite Nanotubes (HNTs)-polymer composites have attracted a lot of attention due to their high surface-to-volume ratio, low density, and high hydrophilicity, and are easily dispersed in hydrophilic biopolymers. In addition, their ability to carry enough amounts of drugs and the ability to control release has been demonstrated. Based on studies, the Gelatin-based scaffold with Halloysite nanotube (HNT) has the capacity as a drug carrier and Zoledronic acid (ZA) sustains release. Previous studies show that using ZA intravenously has some severe side effects and limitations. But by attention to the advantages of its osteogenesis, the current study has been done in order to reduce the side effects of local delivery of it. The 3-dimensional scaffolds were prepared by the Freeze-drying method. Characterization methods such as FE-SEM, FTIR, XRD, and release behavior of the scaffold has been performed to evaluate the features of the scaffolds. In fact, as-prepared Gel-HNT/ZA release 49% ZA in Phosphate Buffered Saline (PBS) within 21 days. The mechanical properties have been increased after adding HNTs and ZA from 10.27 to 26.18 MPa. Also, the water absorption has been increased after adding HNTs and ZA from 1.67 to 5.02 (g/g). Seeded human Adipose stem cells (hASCs) on the prepared scaffolds showed that the ZA effectively elevated the proliferation of the hASCs and also the MTT results proved the non-toxicity of all prepared scaffolds by high cell viability (˃80%). The osteogenic differentiation has been accelerated as displayed by ALP and Ca assay. The results propose that the HNTs-loaded Gelatin scaffold could control the releasing of ZA and its localized delivery at the defect site, simultaneously promoting the mechanical and osteogenesis ability of gelatin-based scaffolds.

show abstract

Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta

Liu

Lee

Nagamani

et al. 2023

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context Osteogenesis Imperfecta (OI) is a genetic disorder characterized by increased bone fragility largely caused by defects in structure, synthesis, or post-translational processing of type I collagen. The effectiveness of medications used for fracture reduction in adults with OI is understudied and practice recommendation not well-established. Objective This review summarizes current knowledge on pharmacologic treatment options for reducing fracture risk in adults with OI. Methods A PubMed online database search of all study types published in the English language using the terms “osteogenesis imperfecta,” “OI,” and “brittle bone disease” was performed in June 2022. Articles screened were restricted to adults. Additional sources were identified through manual searches of reference lists. Pharmaceutical treatment options Drugs currently used to improve skeletal health in OI were initially developed to treat osteoporosis. Oral and intravenous bisphosphonates have been shown to improve bone mineral density (BMD) in adults with OI and are commonly used; however, conclusive data confirming fracture protection are lacking. Similarly, teriparatide appears to increase BMD, an effect that seems to be limited to individuals with type I OI. The role of denosumab, abaloparatide, romosozumab and estradiol/testosterone in adult OI have not been systematically studied. Anti-sclerostin agents and TGF-β antagonists are under investigation in clinical trials. Conclusion Fracture rates are elevated in adults with OI. Although clinical trial data are limited, bisphosphonates and teriparatide may be useful in improving BMD. Further research is needed to develop medications for adults with OI that will lead to definite fracture rate reduction.

show abstract

Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up

Cited by 3 publications

References 29 publications

Vitamin D and Osteogenesis Imperfecta in Pediatrics

Vitamin D and Osteogenesis Imperfecta in Pediatrics

Osteogenesis Improvement of Gelatin-Based Nanocomposite Scaffold by Loading Zoledronic Acid

Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta

Contact Info

Product

Resources

About